CHF0.0015 trade in IGPH.SW IGEA Pharma (SIX) Mar 2026: Heavy volume, liquidity

IGPH.SW stock is trading at CHF0.0015 intraday on 13 Mar 2026 after a 25.00% drop from the prior close. Volume is unusually large at 2,033,000 shares versus an average of 193,941, making IGPH.SW one of the most active names on SIX today. The move reflects severe liquidity swings in a tiny market-cap name and limited public news. Traders should weigh thin liquidity and negative fundamentals before entering positions.

Intraday flow and most active metrics for IGPH.SW stock

IGPH.SW stock shows 2,033,000 shares traded versus an average 193,941, a relative volume of 10.48. The intraday range is CHF0.0015 low to CHF0.0020 high, with the last print at CHF0.0015.

High turnover in a low-price security typically signals liquidity trades and stop clusters. For intraday strategies this raises execution risk and wider spreads on SIX in CHF.

Price action drivers and trading context for IGPH.SW stock

Today’s -25.00% change on IGPH.SW stock is not tied to a scheduled earnings release. No new company filings were posted with the exchange at the time of writing. Market moves appear driven by supply-demand imbalances and block trades.

Given the company’s small float and market cap of CHF505,545.00, even modest order flows can swing price sharply. Traders should treat intraday signals here as high-volatility noise unless paired with company news.

Fundamentals and valuation snapshot for IGPH.SW stock

IGEA Pharma N.V. reports EPS -0.03 and a negative PE ratio of -0.05, reflecting losses. Price averages are weak: 50-day CHF0.00214 and 200-day CHF0.00517, both above today’s trade.

Balance sheet metrics show constrained liquidity. Current ratio is 0.19 and cash per share is minimal. These fundamentals help explain why institutional interest is limited and volatility is high on SIX in CHF.

Technical and liquidity signals impacting IGPH.SW stock

Short-term technicals show the stock trading below both the 50-day and 200-day averages. Year high is CHF0.050 and year low is CHF0.0005, indicating a wide historical range.

Low free float and average volume of 193,941 amplify intraday moves. For active traders, slippage and order partial fills are common on SIX when relative volume spikes.

Meyka grade and model forecast for IGPH.SW stock

Meyka AI rates IGPH.SW with a score out of 100: 62.59 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a 12-month reference view of CHF0.0050. Versus the current CHF0.0015, that implies an upside of 233.33%. Forecasts are model-based projections and not guarantees.

Risk, sector context and trading playbook for IGPH.SW stock

IGPH.SW sits in the Healthcare sector and the Medical – Diagnostics & Research industry. The sector average P/B is roughly 1.96, while IGPH shows negative book value per share. Sector peers have deeper liquidity and steadier margins.

Key risks: tiny market cap, negative earnings, low current ratio, and sparse public disclosure. For intraday traders the playbook is tight: limit orders, small size, and strict stop rules on SIX in CHF.

Final Thoughts

IGPH.SW stock is a high-risk, high-volatility intraday name on SIX today. The last trade at CHF0.0015 and a 2,033,000 share print made it one of the most active Swiss-listed small-caps in CHF. Fundamentals are weak, with EPS -0.03 and negative valuation ratios. Meyka AI rates IGPH.SW 62.59/100 (B, HOLD) and the Meyka AI forecast model projects CHF0.0050 over 12 months. That projection implies a theoretical upside of 233.33% versus the current price, but this view assumes execution and funding improvements. Traders focused on intraday activity should prioritise liquidity controls, use limit orders on SIX, and expect wide spreads. Investors seeking exposure to IGEA Pharma N.V. should treat any forecast as model-driven, not guaranteed, and verify company filings at the source before acting. For company details see IGEA Pharma website and for SIX market rules consult SIX Group. Meyka AI provides this as an AI-powered market analysis platform and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.